The risk group systems aimed for treatment optimalization, are based on patients’ age, tumour location, histology, stage, and molecular changes such as N-myc status, chromosomal and single gene abnormalities (ALK, Aurora K) [19,20,21]. Here, MYCN is linked to neoplasm.